Imaging studies offer the potential for noninvasive detection of key molecules that are important in cancer biology and critical to the advancement of medicine. The goal of the Core Facility CF4. Koutcher: Animal Imaging is to provide imaging research support to SPORE investigators who are involved in defining prostate cancer signature, often at the molecular level. Imaging studies may serve as a noninvasive phenotypic correlate of the molecular changes. The primary responsibility of CF4. Koutcher: Animal Imaging will be to provide PET, and magnetic resonance (MR) imaging/spectroscopy capability at the highest spatial resolution possible to monitor the effect of molecular changes. We will upgrade our MR equipment with stronger gradients (28 G/cm insert has just been delivered; 100 G/cm insert for higher spatial resolution is proposed), NIH funding has been obtained for a new spectrometer console to replace our antiquated system. A new vertical bore 500 MHZ system with dedicated microscopy insert is being planned and will provide higher signal to noise and further improvements in image resolution. A new MicroPet has been ordered and delivery is expected shortly. This instrument will have isotropic 2-mm resolution (voxel = 8mm3). The MicroPET will be used to study llC-choline, llC-methionine, 18F-fluorodeoxyglucose, 18F-fluorodihydrotestosterone and 124Iiododeoxyuridine and the imaging studies will be correlated with pathologic data. Quantitative autoradiography equipment has also been upgraded and will complement the PET and MR. The upgrade to the QAR system will allow simultaneous imaging of three nuclei within the same sample. Further support, e.g., physiological monitoring, image correlation, will be necessary for the successful implementation of this project and will need to be developed. As a core facility, a main goal will be providing state-of-the-art imaging capability. This will include in vivo spatial resolution of between 50 to 100?u in plane and 0.25-0.5 mm slice thickness for MR, greater than 8mm3 voxels for the MicroPET and 3 nuclide imaging in QAR. To increase MR spatial resolution further, more sensitive radio-frequency coils will be designed. Improvements in image processing and analysis to enhance the accuracy of multi-modality imaging will also be necessary. The lack of anatomical detail provided by PET necessitates the development of good software for correlating PET, MRI, and QAR data, in addition to histochemical/anatomic data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA092629-02S1
Application #
6664526
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-10
Project End
2003-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Roobol, Monique J; Carlsson, Sigrid V (2018) The ERSPC Study: Quality Takes Time and Perseverance. Clin Chem :
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467
Van Calster, Ben; Wynants, Laure; Verbeek, Jan F M et al. (2018) Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol 74:796-804
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Frånlund, Maria; Arnsrud Godtman, Rebecka; Carlsson, Sigrid V et al. (2018) Prostate cancer risk assessment in men with an initial P.S.A. below 3?ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial. Scand J Urol 52:256-262
Mikropoulos, Christos; Selkirk, Christina G Hutten; Saya, Sibel et al. (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118:266-276
Capogrosso, Paolo; Vertosick, Emily A; Benfante, Nicole E et al. (2018) Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. Eur Urol :
Lee, Justin K; Sjoberg, Daniel D; Miller, Mariam Imnadze et al. (2018) Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients? Eur Urol 73:33-37

Showing the most recent 10 out of 505 publications